Coming December: ASH publishes its late-breaking abstracts. We’ll add the organizations presenting them.

Novo Nordisk at ASH 2026

Dec 12–15, 2026 New Orleans, LA ~30k attendees Website

Novo Nordisk brings 8 presentations to ASH 2026 in New Orleans, and exhibits at Booth 913. Novo Nordisk presents sessions on hemophilia management and its sickle cell drug development, and supports a symposium on sickle cell therapies. Research covers patient preferences in hemophilia and etavopivat.

OrganizationASH 2026 Attendance
Novo Nordisk
Bagsværd, Denmark
Large pharma
Danish pharmaceutical company; its rare disease unit develops treatments for hemophilia and other rare blood disorders, including sickle cell disease.
Booth
Exhibiting at Booth 913
Sat, Dec 1211:00am–5:00pmSun, Dec 1310:00am–5:00pmMon, Dec 1410:00am–2:00pm
Symposium
Fri Dec 11
7:00am–10:00am
A Hematologist’s Guide to the Sickle Cell Disease Revolution: Genes, Activators, and Beyond
Approved and emerging gene therapies and new pyruvate kinase activators for sickle cell disease, and how to match patients to each and refer them.
Red cells · Cell & gene

Explore the full ASH 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in New Orleans. Leave your work email and we’ll be in touch.

Privacy

Download the full ASH 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Find decision makers at Novo Nordisk

Tell us what you sell and we’ll find the people at Novo Nordisk most likely to buy it.

  • Who to contact
  • Their contact info
  • What to say
  • Free, no sign-up

Not affiliated with or endorsed by the American Society of Hematology (ASH). Submit a correction